Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

This protocol will investigate the effectiveness of plerixafor in the up-front setting in avoiding a second round of mobilization and whether this translates into a clinical and economic benefit.

Further Study Information

Peripheral blood stem cells are now considered the standard source of stem cells for autologous stem cell transplants. Unfortunately, there is still a 20-30% chance that inadequate numbers of stem cells will be collected, resulting in prolonged recovery of cell counts after transplantation and increased transfusion dependence. There is also a significant economic burden associated with remobilization and a risk that delays in collecting sufficient numbers of stem cells can result in an increased chance of disease recurrence prior to transplantation.

Eligibility Criteria

Inclusion Criteria:

• Patients with multiple myeloma or non-Hodgkin's lymphoma with a planned autologous transplant and who are eligible for peripheral stem cell mobilization.

• Karnofsky Performance Status ≥ 70.

• Age ≥ 18

• Less than 30% involvement of marrow with disease.

Exclusion Criteria:

• > 30% marrow involvement with disease

• Age < 18.

• Pregnant women.

Trial Contact Information

Trial Lead Organizations/Sponsors

University of Florida Shands Cancer Center

Jack W Hsu, MD

Principal Investigator

Christine NeJame, RN		Ph: 352-273-6838
		Email: cnejame@ufl.edu

U.S.A.
Florida
	Gainesville
	University of Florida Shands Cancer Center
		Christine NeJame, RN	Ph: 352-273-6838
		Jack W Hsu, MD	Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01339572
Information obtained from ClinicalTrials.gov on September 25, 2012

Back to Top